Drugs

Article	Citations
Prevention and Treatment of Monkeypox	298
BNT162b2 mRNA COVID-19 Vaccine: First Approval	219
Tazemetostat: First Approval	190
Pharmaco-Immunomodulatory Therapy in COVID-19	189
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	165
Inclisiran: First Approval	165
Lumasiran: First Approval	163
Remdesivir: First Approval	162
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	155
Nirmatrelvir Plus Ritonavir: First Approval	152
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	148
Sacituzumab Govitecan: First Approval	130
Casimersen: First Approval	128
Trastuzumab Deruxtecan: First Approval	123
Pemigatinib: First Approval	122
Aducanumab: First Approval	112
Viltolarsen: First Approval	111
Sotorasib: First Approval	110
Risdiplam: First Approval	97
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	91
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma	90
Setmelanotide: First Approval	89
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	86
Selpercatinib: First Approval	86
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	85

Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?	83
Bulevirtide: First Approval	83
TRPV1-Targeted Drugs in Development for Human Pain Conditions	82
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	81
Acute Pancreatitis: Diagnosis and Treatment	81
Belantamab Mafodotin: First Approval	80
Orelabrutinib: First Approval	78
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	78
Pharmacokinetics and Pharmacodynamics of Posaconazole	77
Remimazolam: First Approval	77
Ozanimod: First Approval	71
Tislelizumab: First Approval	71
New and Emerging Systemic Treatments for Atopic Dermatitis	71
Inhaled Liposomal Antimicrobial Delivery in Lung Infections	70
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review	69
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer	69
Delgocitinib: First Approval	68
Nivolumab Plus Relatlimab: First Approval	67
Tirabrutinib: First Approval	66
REGN-EB3: First Approval	65
Fabry Disease: The Current Treatment Landscape	64
Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments	63
Lonafarnib: First Approval	63
Amivantamab: First Approval	62
Pralsetinib: First Approval	62
ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials	61
Selumetinib: First Approval	61
Capmatinib: First Approval	60
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety	60
Decitabine/Cedazuridine: First Approval	58
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	58
Inebilizumab: First Approval	58
Belzutifan: First Approval	57
Bempedoic Acid: First Approval	57
Savolitinib: First Approval	56
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma	53
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	53
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review	52
Tepotinib: First Approval	50
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases	50
Targeting AMPK by Statins: A Potential Therapeutic Approach	50
Casirivimab/Imdevimab: First Approval	50
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	50
Remimazolam: A Review in Procedural Sedation	49
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	48
Molnupiravir: First Approval	48
Deucravacitinib: First Approval	48
Faricimab: First Approval	48
Tucatinib: First Approval	47
Abrocitinib: First Approval	46

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation	46
Tisotumab Vedotin: First Approval	46
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma	46
Management of Thrombotic Complications in COVID-19: An Update	45
Disitamab Vedotin: First Approval	44
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis	44
The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19	44
Filgotinib: First Approval	44
Ripretinib: First Approval	44
Loncastuximab Tesirine: First Approval	44
Dostarlimab: First Approval	44
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer	43
Trilaciclib: First Approval	43
Lurbinectedin: First Approval	43
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	43
Cabotegravir Plus Rilpivirine: First Approval	42
Efgartigimod: First Approval	42
Current Status of Clinical Trials on Tau Immunotherapies	42
Umbralisib: First Approval	42
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	42
Telitacicept: First Approval	42
Pegcetacoplan: First Approval	41
Infigratinib: First Approval	41
Vutrisiran: First Approval	41
Contezolid: First Approval	41
Odevixibat: First Approval	41
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review	41
Isatuximab: First Approval	40
Naxitamab: First Approval	40
Therapeutic Options in Hereditary Optic Neuropathies	40
Daprodustat: First Approval	39
Cenegermin: A Review in Neurotrophic Keratitis	39
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations	39
Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon	38
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder	38
Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma	38
Tirzepatide: First Approval	38
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections	38
Envafolimab: First Approval	38
Regdanvimab: First Approval	37
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics	37
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs	37
Givosiran: A Review in Acute Hepatic Porphyria	37
Anifrolumab: First Approval	36
Teprotumumab: First Approval	36
Lecanemab: First Approval	36
Evinacumab: First Approval	35
Eptinezumab: First Approval	35
Functional Dyspepsia: Diagnostic and Therapeutic Approaches	35
Satralizumab: First Approval	35
Rimegepant: First Approval	35
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents	35
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals	34
Voclosporin: First Approval	34
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?	34
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy	33
Tebentafusp: First Approval	33
Lazertinib: First Approval	33
Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates	33
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists	33
Ocrelizumab: A Review in Multiple Sclerosis	33
Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?	32
Tremelimumab: First Approval	32
Vadadustat: First Approval	32
Tezepelumab: First Approval	32
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review	32
Osilodrostat: First Approval	32
Sotrovimab: First Approval	31
Melphalan Flufenamide (Melflufen): First Approval	31
Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza	31
Asciminib: First Approval	31
Fuzuloparib: First Approval	31
Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps	30
Daridorexant: First Approval	30
Spesolimab: First Approval	30
Finerenone: First Approval	30
Mavacamten: First Approval	30
Pamiparib: First Approval	30
Oliceridine: First Approval	29
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease	29

Mobocertinib: First Approval	29
Tixagevimab + Cilgavimab: First Approval	29
Belumosudil: First Approval	28
Mosunetuzumab: First Approval	28
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	28
Nirsevimab: First Approval	28
Vericiguat: First Approval	28
Advances in Long-Acting Agents for the Treatment of HIV Infection	28
Maralixibat: First Approval	28
Cadonilimab: First Approval	28
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry	28
Difelikefalin: First Approval	28
Ansuvimab: First Approval	27
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents	27
Avacopan: First Approval	27
Uveitis Therapy: The Corticosteroid Options	27
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	27
Olverembatinib: First Approval	26
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections	26
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	26
Mirvetuximab Soravtansine: First Approval	26
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa	25
Atogepant: First Approval	25
Ozoralizumab: First Approval	25
Novel Approaches Towards a Functional Cure of HIV/AIDS	25
Teclistamab: First Approval	25
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	25
Ibrexafungerp: First Approval	25